|
|
Line 1: |
Line 1: |
| The BIMIB group (bimib.disco.unimib.it) has become involved in a multidisciplinary project involving five different Institutions in Italy and UK. This ambitious project, entitled “Single-cell cancer evolution in the clinic”, aims at studying the evolutionary trajectories of cell clones in cancer tissues and in patient-derived organoids, in order to define effective and data-driven personalized therapeutic strategies, and it is funded by a joint Cancer Research UK (CRUK), Asociación Española Contra el Cáncer (FA-AECC) and Associazione Italiana per la Ricerca sul Cancro (AIRC) Accelerator Award. | | The BIMIB group (bimib.disco.unimib.it) has become involved in a multidisciplinary project involving five different Institutions in Italy and UK. This ambitious project, entitled “Single-cell cancer evolution in the clinic”, aims at studying the evolutionary trajectories of cell clones in cancer tissues and in patient-derived organoids, in order to define effective and data-driven personalized therapeutic strategies, and it is funded by a joint Cancer Research UK (CRUK), Asociación Española Contra el Cáncer (FA-AECC) and Associazione Italiana per la Ricerca sul Cancro (AIRC) Accelerator Award. |
| + | |
| + | |
| + | <!-- |
| | | |
| == '''We are hiring''' == | | == '''We are hiring''' == |
| | | |
− | <!--
| + | |
| | | |
| === Post Doc === | | === Post Doc === |
Latest revision as of 19:40, 10 December 2020
The BIMIB group (bimib.disco.unimib.it) has become involved in a multidisciplinary project involving five different Institutions in Italy and UK. This ambitious project, entitled “Single-cell cancer evolution in the clinic”, aims at studying the evolutionary trajectories of cell clones in cancer tissues and in patient-derived organoids, in order to define effective and data-driven personalized therapeutic strategies, and it is funded by a joint Cancer Research UK (CRUK), Asociación Española Contra el Cáncer (FA-AECC) and Associazione Italiana per la Ricerca sul Cancro (AIRC) Accelerator Award.